Top 10 Companies in the Montelukast Sodium Market (2026): Market Leaders Shaping Global Respiratory Care

MARKET INSIGHTS

Montelukast Sodium Market – View in Detailed Research Report

Global Montelukast Sodium market size was valued at USD 358 million in 2024 and is projected to grow from USD 413 million in 2025 to USD 882 million by 2032, exhibiting a CAGR of 14.1% during the forecast period.

Montelukast sodium is a leukotriene receptor antagonist used for prophylaxis and chronic treatment of respiratory conditions including asthma, allergic rhinitis, and exercise‑induced bronchoconstriction. The hygroscopic white powder demonstrates high solubility in ethanol, methanol, and water while being practically insoluble in acetonitrile.

The market growth is primarily driven by increasing respiratory disease prevalence globally, with the WHO estimating 339 million asthma sufferers worldwide. While North America currently leads market revenue due to high treatment adoption rates, Asia‑Pacific shows accelerated growth potential because of expanding healthcare infrastructure and rising pollution‑related respiratory issues. Morepen Laboratories dominates the competitive landscape with 22% market share, followed by Mylan and other key manufacturers investing in API production and formulation development to meet growing demand.

Top 10 Companies in the Montelukast Sodium Market

🔟 1. Morepen Laboratories

Headquarters: Chennai, India
Key Offering: Montelukast sodium tablets, chewable tablets, and oral solutions

Morepen Laboratories has built a robust supply chain that spans raw material sourcing to finished dosage forms. Its integrated manufacturing footprint allows rapid scale‑up during periods of heightened demand, a feature that has kept it ahead of competitors during recent market surges.

Morepen focuses on continuous process improvement and has recently introduced a new crystallisation technique that boosts yield by 8%. The company also invests in green chemistry initiatives, reducing solvent usage by 12% across its production lines.

• Advanced crystallisation process improving yield
• Green chemistry initiatives cutting solvent use
• Strategic partnerships with local distributors in Southeast Asia
• Expansion of API manufacturing capacity by 25% in 2025

9️⃣ 2. Mylan (now part of Viatris)

Headquarters: Dublin, Ireland
Key Offering: Generic Montelukast sodium tablets and combination products with antihistamines

Mylan’s global reach is underpinned by a strong regulatory portfolio. The company’s recent launch of a fixed‑dose combination product has broadened its appeal to patients seeking simplified regimens.

Viatris is investing in digital health integration, offering a mobile platform that tracks medication adherence and sends reminders to patients.

• Fixed‑dose combination product launch
• Digital adherence tracking platform
• Global regulatory approvals in 18 markets
• API production expansion in India and Brazil

8️⃣ 3. TAPI (Teva Active Pharmaceutical Ingredients)

Headquarters: Tel Aviv, Israel
Key Offering: High‑purity Montelukast sodium API

TAPI’s API is prized for its purity and consistent batch performance, which translates into higher drug efficacy for end‑product manufacturers.

The company is exploring continuous manufacturing techniques to reduce cycle time and lower production costs.

• High‑purity API supply to global manufacturers
• Investment in continuous manufacturing
• Strategic collaborations with Indian OEMs
• Expansion of production capacity by 30% in 2026

7️⃣ 4. MSN Laboratories

Headquarters: Chennai, India
Key Offering: Montelukast sodium tablets and chewable formulations

MSN Laboratories has positioned itself as a cost‑competitive player, leveraging its extensive network of contract manufacturing facilities.

Recent initiatives include the adoption of a new quality management system that has cut non‑conforming rates by 15%.

• Cost‑competitive manufacturing model
• New quality management system
• Partnerships with hospitals in India and Vietnam
• Launch of a new pediatric formulation in 2025

6️⃣ 5. Ultratech India

Headquarters: Hyderabad, India
Key Offering: Montelukast sodium API and finished dosage forms

Ultratech India has expanded its API production to meet the rising demand in emerging markets, focusing on process optimisation to maintain competitive pricing.

The firm is also investing in a digital supply‑chain platform that provides real‑time inventory visibility to distributors.

• Expanded API production capacity
• Digital supply‑chain platform
• Strategic alliances with distributors in Latin America
• Reduced production cost per unit by 5% in 2026

5️⃣ 6. Aurobindo Pharma

Headquarters: Hyderabad, India
Key Offering: Montelukast sodium tablets and combination products

Aurobindo has leveraged its strong distribution network to maintain a steady market share across India and the United States.

Recent product launches include a taste‑masking chewable tablet aimed at improving pediatric adherence.

• Taste‑masking chewable tablet launch
• Strong distribution network in India and the U.S.
• Investment in R&D for combination therapies
• Expansion of manufacturing footprint in 2025

4️⃣ 7. Hetero Labs

Headquarters: Ahmedabad, India
Key Offering: Montelukast sodium tablets and chewable formulations

Hetero Labs has focused on maintaining a robust pricing strategy to compete in price‑sensitive markets while ensuring product quality.

The company is also exploring the use of biodegradable packaging to align with growing environmental regulations.

• Competitive pricing strategy
• Biodegradable packaging initiatives
• Partnerships with hospitals in South Asia
• API production capacity expansion by 20% in 2026

3️⃣ 8. Unimark Remedies

Headquarters: Mumbai, India
Key Offering: Montelukast sodium tablets and oral solutions

Unimark Remedies has carved out a niche in the Indian market through aggressive local marketing campaigns and a strong focus on patient education.

Recent efforts include a tele‑pharmacy platform that offers remote consultations and medication delivery.

• Tele‑pharmacy platform launch
• Patient education campaigns
• Local marketing focus in India
• Partnership with retail pharmacies in 2025

2️⃣ 9. Jubilant Cadista

Headquarters: Chicago, Illinois, USA
Key Offering: Montelukast sodium tablets and combination products

Jubilant Cadista has leveraged its expertise in advanced manufacturing to deliver high‑quality products to the U.S. market.

The company is also investing in research for potential new indications, such as chronic obstructive pulmonary disease (COPD).

• Advanced manufacturing capabilities
• Research into COPD indications
• Strong regulatory approvals in the U.S.
• Expansion of U.S. distribution network in 2026

1️⃣ 10. Hengyuan Pharmaceutical

Headquarters: Shanghai, China
Key Offering: Montelukast sodium tablets and chewable formulations

Hengyuan has positioned itself as a leading API supplier in China, with a focus on cost efficiency and process scalability.

The firm is exploring partnerships with local hospitals to support clinical trials for expanded indications.

• Cost‑efficient API production
• Process scalability initiatives
• Partnerships with local hospitals for clinical trials
• Expansion of production capacity by 15% in 2026

Montelukast Sodium Market – View in Detailed Research Report

Montelukast Sodium Market – View in Detailed Research Report

Outlook

• North America remains the largest revenue contributor, driven by high prevalence of asthma and robust healthcare infrastructure.
• Asia‑Pacific is the fastest‑growing region, with India and China capturing the majority of new market share.
• Emerging markets in Southeast Asia, Africa, and Latin America present significant untapped opportunities, with penetration rates below 40% of the addressable patient population.
• Digital health integration is reshaping the value chain, creating new revenue streams through adherence tracking and remote monitoring.
• Competitive pricing pressures continue to compress margins, prompting manufacturers to focus on cost‑effective production and process optimisation.

Future Trends

• Expansion of fixed‑dose combination products to improve patient compliance.
• Broader therapeutic applications beyond respiratory conditions, including potential roles in COVID‑19 sequelae and neuro‑inflammatory disorders.
• Increased focus on pediatric formulations, with taste‑masking and chewable options leading the way.
• Greater emphasis on green chemistry and sustainable manufacturing practices across the supply chain.
• Adoption of advanced analytics for real‑time supply‑chain management and demand forecasting.